Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2018

01-01-2018 | Original Article – Clinical Oncology

Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

Authors: Shenhai Wei, Jintao Tian, Xiaoping Song, Bingqun Wu, Limin Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2018

Login to get access

Abstract

Purpose

To investigate the probability of death (POD) from any causes by time after diagnosis of non-small cell lung cancer (NSCLC) and the factors associated with survival for NSCLC patients.

Methods

A total of 202,914 patients with NSCLC from 2004 to 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The overall survival (OS) and lung cancer-specific survival (LCSS) were calculated and POD from any causes at different time periods after diagnosis was explored. The predictive factors for OS, LCSS and survival from non-lung cancer deaths were investigated using multivariate analysis with Cox proportional hazards regression and competing risk regression analysis.

Results

The 5- and 10-year OS were 20.4% and 11.5%, accordingly that for LCSS were 25.5% and 18.4%, respectively. Lung cancer contributed 88.3% (n = 128,402) of the deaths. The POD from lung cancer decreased with time after diagnosis. In multivariate analysis, advanced age and advanced stage of NSCLC were associated with decreased OS and LCSS. Comparing to no surgery, any kind of resection conferred lower risk of death from lung cancer and higher risk of dying from non-lung cancer conditions except lobectomy or bilobectomy, which was associated with lower risk of death from both lung cancer and non-lung cancer conditions.

Conclusions

Most of the patients with NSCLC died from lung cancer. Rational surveillance and treatment policies should be made for them. Early stage and lobectomy or bilobectomy were associated with improved OS and LCSS. It is reasonable to focus on early detection and optimal surgical treatment for NSCLC.
Literature
go back to reference Alexiou C et al (2003) Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. Ann Thorac Surg 76:1023–1028CrossRefPubMed Alexiou C et al (2003) Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. Ann Thorac Surg 76:1023–1028CrossRefPubMed
go back to reference Butts CA et al (2010) Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28:29–34. doi:10.1200/jco.2009.24.0333 CrossRefPubMed Butts CA et al (2010) Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28:29–34. doi:10.​1200/​jco.​2009.​24.​0333 CrossRefPubMed
go back to reference Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014–4021. doi:10.1200/jco.2010.32.6462 CrossRefPubMed Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014–4021. doi:10.​1200/​jco.​2010.​32.​6462 CrossRefPubMed
go back to reference Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
go back to reference Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg 60:615–622 (discussion 622–613) CrossRef Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg 60:615–622 (discussion 622–613) CrossRef
go back to reference Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2016) SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2016) SEER cancer statistics review, 1975–2013, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2013/​, based on November 2015 SEER data submission, posted to the SEER web site, April 2016
go back to reference Hubbard MO, Fu P, Margevicius S, Dowlati A, Linden PA (2012) Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg 143:1307–1313. doi:10.1016/j.jtcvs.2012.01.078 CrossRefPubMed Hubbard MO, Fu P, Margevicius S, Dowlati A, Linden PA (2012) Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg 143:1307–1313. doi:10.​1016/​j.​jtcvs.​2012.​01.​078 CrossRefPubMed
go back to reference Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ, Coebergh JW (2004) Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59:602–607CrossRefPubMedPubMedCentral Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ, Coebergh JW (2004) Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59:602–607CrossRefPubMedPubMedCentral
go back to reference Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ (2015) Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 26:902–907. doi:10.1093/annonc/mdv061 CrossRefPubMed Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ (2015) Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 26:902–907. doi:10.​1093/​annonc/​mdv061 CrossRefPubMed
go back to reference Johnson BE (1998) Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90:1335–1345CrossRefPubMed Johnson BE (1998) Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90:1335–1345CrossRefPubMed
go back to reference Newschaffer CJ, Otani K, McDonald MK, Penberthy LT (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92:613–621CrossRefPubMed Newschaffer CJ, Otani K, McDonald MK, Penberthy LT (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92:613–621CrossRefPubMed
go back to reference Rodriguez M, Gomez MT, Jimenez MF, Aranda JL, Novoa N, Varela G (2013) The risk of death due to cardiorespiratory causes increases with time after right pneumonectomy: a propensity score-matched analysis. Eur J Cardio Thorac Surg 44:93–97. doi:10.1093/ejcts/ezs620 CrossRef Rodriguez M, Gomez MT, Jimenez MF, Aranda JL, Novoa N, Varela G (2013) The risk of death due to cardiorespiratory causes increases with time after right pneumonectomy: a propensity score-matched analysis. Eur J Cardio Thorac Surg 44:93–97. doi:10.​1093/​ejcts/​ezs620 CrossRef
go back to reference Zhang Y, Sun Y, Wang R, Ye T, Zhang Y, Chen H (2015) Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage I non-small cell lung cancer. J Surg Oncol 111:334–340. doi:10.1002/jso.23800 CrossRefPubMed Zhang Y, Sun Y, Wang R, Ye T, Zhang Y, Chen H (2015) Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage I non-small cell lung cancer. J Surg Oncol 111:334–340. doi:10.​1002/​jso.​23800 CrossRefPubMed
go back to reference Zippin C, Lum D, Hankey BF (1995) Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343–2350CrossRefPubMed Zippin C, Lum D, Hankey BF (1995) Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343–2350CrossRefPubMed
Metadata
Title
Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database
Authors
Shenhai Wei
Jintao Tian
Xiaoping Song
Bingqun Wu
Limin Liu
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2522-3

Other articles of this Issue 1/2018

Journal of Cancer Research and Clinical Oncology 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.